Beyond the conventional focus on amyloid beta and tau pathology, investigators are actively identifying novel therapeutic avenues for the disease. These feature regulating brain inflammation through reducing glial response, interacting with neuronal impairment – particularly related to excitatory neurotransmitter transmission – and investigatin